Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

Krista L. Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, Steven E. Arnold, Clive Ballard, Jiska Cohen-Mansfield, Zahinoor Ismail, Constantine Lyketsos, David S. Miller, Erik Musiek, Ricardo S. Osorio, Paul B. Rosenberg, Andrew Satlin, David Steffens, Pierre Tariot, Lisa J. Bain, Maria C. Carrillo, James A. Hendrix, Heidi Jurgens, Brendon Boot

Research output: Contribution to journalReview articlepeer-review

207 Scopus citations


Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.

Original languageEnglish
Pages (from-to)440-449
Number of pages10
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Issue number3
StatePublished - Sep 2017


  • Agitation
  • Alzheimer's disease
  • Apathy
  • Delusions
  • Depression
  • Hallucinations
  • Neuropsychiatric symptoms
  • Sleep disturbance
  • Trial design


Dive into the research topics of 'Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms'. Together they form a unique fingerprint.

Cite this